Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter (Q39480588)

12 September 2017

Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter (English)

1 reference

12 September 2017

1 reference

Poulomi Banerjee

1

1 reference

12 September 2017

Harshini Surendran

2

1 reference

12 September 2017

Debabani Roy Chowdhury

3

1 reference

12 September 2017

Karthik Prabhakar

4

1 reference

12 September 2017

Rajarshi Pal

5

1 reference

12 September 2017

17 August 2016

1 reference

Journal of Molecular Medicine

12 September 2017

1 reference

12 September 2017

94

1 reference

12 September 2017

12

1 reference

12 September 2017

1397-1409

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-016-1455-7

12 September 2017

0 references

cites work

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Mechanisms of drug inhibition of signalling molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Snail family regulation and epithelial mesenchymal transitions in breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Tumor suppressor gene E-cadherin and its role in normal and malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Cadherins and cancer: how does cadherin dysfunction promote tumor progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Vitiligo patient-derived keratinocytes exhibit characteristics of normal wound healing via epithelial to mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

DNA methylation mapping by tag-modified bisulfite genomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Paranuaclear E-cadherin in gastric adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

E-cadherin upregulation as a therapeutic goal in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

The invasion inhibitor sarasinoside A1 reverses mesenchymal tumor transformation in an E-cadherin-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Dysregulation of Wnt-Signaling and a Candidate Set of miRNAs Underlie the Effect of Metformin on Neural Crest Cell Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Versican mediates mesenchymal-epithelial transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Repositioning metformin for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-016-1455-7

Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27534967

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00109-016-1455-7

1 reference

12 September 2017

1 reference